Clinical Trial Update: Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update of dovitinib (TKI258) in patients with relapsed glioblastoma (first or second recurrence).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Dovitinib (dovitinib)

Snippet

Sponsor: PD Dr. Martin Glas | Conditions: First or Second Recurrence of Glioblastoma | Phase 1 | Status: UNKNOWN